Edition:
United Kingdom

CVS Health Corp (CVS.N)

CVS.N on New York Stock Exchange

55.94USD
19 Jul 2019
Change (% chg)

$-0.56 (-0.99%)
Prev Close
$56.50
Open
$56.70
Day's High
$56.82
Day's Low
$55.94
Volume
1,269,579
Avg. Vol
2,321,145
52-wk High
$82.12
52-wk Low
$51.72

Latest Key Developments (Source: Significant Developments)

CVS Health Sets Quarterly Dividend Of $0.50/Share
Wednesday, 10 Jul 2019 

July 10 (Reuters) - CVS Health Corp ::SETS QUARTERLY DIVIDEND OF $0.50PER SHARE.  Full Article

Premier Inc. To Exit Specialty Pharmacy Business
Monday, 6 May 2019 

May 6 (Reuters) - Premier Inc ::PREMIER INC. TO EXIT SPECIALTY PHARMACY BUSINESS.PREMIER INC - TO MOVE REINFORCES STRATEGIC FOCUS ON CORE BUSINESSES.PREMIER INC - RELATED IMPAIRMENT AND EXIT-COST CHARGES EXPECTED TO BE RECORDED IN CURRENT QUARTER.PREMIER INC - WILL SELL CERTAIN ASSETS RELATED TO ITS SPECIALTY PHARMACY BUSINESS FOR $22.5 MILLION, PLUS UP TO ADDITIONAL $20.0 MILLION FOR INVENTORY.PREMIER INC - SALE MADE IN CONNECTION WITH PLANS TO DISCONTINUE SPECIALTY PHARMACY OPERATIONS BY ACRO PHARMACEUTICAL SERVICES, COMMCARE PHARMACY.PREMIER INC - PROCEEDS FROM DEAL TO BE USED PRIMARILY TO FUND COSTS ASSOCIATED WITH DEAL, WIND DOWN & EXIT FROM SPECIALTY PHARMACY OPERATIONS.PREMIER INC -TO RECORD NON-CASH IMPAIRMENT CHARGE OF ABOUT $87 MILLION-$92 MILLION FOR GOODWILL, PURCHASED INTANGIBLES, OTHER ASSETS OF SPECIALTY PHARMACY BUSINESS.PREMIER INC - EXPECTS TO INCUR ONE-TIME, DEAL AND EXIT-RELATED PRE-TAX CHARGES OF ABOUT $11 MILLION-$15 MILLION.PREMIER INC - MONDAY'S ACTIONS EXPECTED TO INCREASE CONSOLIDATED NON-GAAP ADJUSTED EBITDA MARGIN TO ABOUT 45% FOR FULL 2019 FY.PREMIER INC - SOME CONSOLIDATED SUBSIDIARIES ENTERED INTO DEFINITIVE ASSET PURCHASE AND SALE AGREEMENT WITH PROCARE PHARMACY LLC.  Full Article

DFS says Acts Against Health Insurers For Violations Related To Contraceptive Coverage
Friday, 3 May 2019 

May 3 (Reuters) - Department of Financial Services::DFS TAKES ACTION AGAINST HEALTH INSURERS FOR VIOLATIONS OF INSURANCE LAW RELATED TO CONTRACEPTIVE COVERAGE.DFS - INVESTIGATION FINDS THAT TEN HEALTH INSURERS, INCLUDING AETNA AND OXFORD, IMPROPERLY EXEMPTED EMPLOYERS FROM PROVIDING CONTRACEPTIVE COVERAGE.DFS - INSURERS TO PAY $509,000, ISSUE CLAIM RESTITUTION AND REIMBURSEMENTS FOR INSUREDS WHO SHOULD HAVE RECEIVED CONTRACEPTIVE COVERAGE.DFS - INSURERS IMPROPERLY GRANTED RELIGIOUS EMPLOYER EXEMPTION REQUESTS TO MORE THAN 30 ENTITIES THAT DID NOT MEET REQUIREMENTS OF INSURANCE LAW.  Full Article

CVS Health Corp Says CEO Larry Merlo's FY 2018 Total Compensation Was $21.9 Million
Friday, 5 Apr 2019 

April 5 (Reuters) - CVS Health Corp ::CVS HEALTH CORP SAYS CEO LARRY MERLO'S FY 2018 TOTAL COMPENSATION WAS $21.9 MILLION VERSUS $23.3 MILLION IN FY 2017 - SEC FILING.CVS HEALTH CORP SAYS COO JONATHAN ROBERTS' FY 2018 TOTAL COMPENSATION WAS $16.1 MILLION VERSUS $6.9 MILLION IN FY 2017.CVS HEALTH CORP SAYS RATIO OF CEO ANNUAL COMPENSATION TO MEDIAN EMPLOYEE FOR 2018 IS 618-TO-1.  Full Article

Aetna Heads A $25 Mln Investment Round Into Map Health Management
Thursday, 7 Mar 2019 

March 7 (Reuters) - CVS Health Corp ::AETNA HEADS A $25 MILLION INVESTMENT ROUND INTO MAP HEALTH MANAGEMENT.MAP HEALTH MANAGEMENT - COMPLETION OF $25 MILLION PLACEMENT OF SERIES A PREFERRED AND COMMON UNITS IN A ROUND HEADED BY AETNA, A CVS HEALTH BUSINESS.  Full Article

CVS CEO Says Sees Proposed Rebate Rule "Taking Us Backwards Not Forward"
Wednesday, 20 Feb 2019 

Feb 20 (Reuters) - CVS Health Corp ::CVS HEALTH CORP SAYS PRICES FOR NON SPECIALTY MEDICATIONS FELL 4.2 PERCENT FOR COMMERCIAL CLIENTS; PRICES FOR SPECIALTY PRODUCTS GREW 1.7 PERCENT IN 2018.CVS HEALTH CORP SAYS OPERATING INCOME FOR PBM BUSINESS WILL BE DOWN MID-SINGLE DIGITS VERSUS 2018 - CONF. CALL.CVS SAYS ANTHEM PBM CONTRACT IS A "STRONG HEADWIND" DUE TO INVESTMENT NEEDED TO ACCELERATE START DATE.CVS CEO SAYS SEES PROPOSED REBATE RULE "TAKING US BACKWARDS NOT FORWARD" - CONF. CALL.  Full Article

CVS Health Reports Q4 Adjusted Earnings Per Share Of $2.14
Wednesday, 20 Feb 2019 

Feb 20 (Reuters) - CVS Health Corp ::CVS HEALTH REPORTS FOURTH QUARTER AND FULL YEAR RESULTS AND PROVIDES 2019 FULL YEAR GUIDANCE.Q4 ADJUSTED EARNINGS PER SHARE $2.14.Q4 GAAP LOSS PER SHARE $0.37 FROM CONTINUING OPERATIONS.Q4 EARNINGS PER SHARE ESTIMATE $2.05 -- REFINITIV IBES DATA.SEES FY 2019 ADJUSTED EARNINGS PER SHARE $6.68 TO $6.88.SEES FY 2019 GAAP EARNINGS PER SHARE $4.88 TO $5.08 FROM CONTINUING OPERATIONS.QTRLY REVENUES INCREASED 12.5% TO $54.4 BILLION.CVS HEALTH - SEES 2019 CASH FLOW FROM OPERATIONS BETWEEN $9.8 BILLION TO $10.3 BILLION.Q4 GAAP LOSS PER SHARE FROM CONTINUING OPERATIONS INCLUDED A $2.2 BILLION, OR $1.99 PER SHARE, GOODWILL IMPAIRMENT CHARGE RELATED TO LTC BUSINESS.Q4 REVENUE VIEW $54.58 BILLION -- REFINITIV IBES DATA.  Full Article

Omega Advisors Reports Share Stake Of 795,900 Shares In CVS Health As Of Dec 31 Vs 394,600 Shares As Of Sept 30
Thursday, 14 Feb 2019 

Feb 14 (Reuters) - Omega Advisors: :OMEGA ADVISORS REPORTS SHARE STAKE OF 795,900 SHARES IN CVS HEALTH CORP AS OF DEC 31 VERSUS 394,600 SHARES AS OF QUARTER ENDED SEPT 30, 2018 - SEC FILING.OMEGA ADVISORS - CHANGE IN HOLDINGS ARE AS OF DECEMBER 31, 2018 AND COMPARED WITH THE PREVIOUS QUARTER ENDED AS OF SEPTEMBER 30, 2018.  Full Article

Aetna Announces Attain, Which Combines Health History With Apple Watch Information
Tuesday, 29 Jan 2019 

Jan 29 (Reuters) - CVS Health -:AETNA ANNOUNCES ATTAIN, A PERSONALIZED WELL-BEING EXPERIENCE THAT COMBINES HEALTH HISTORY WITH APPLE WATCH INFORMATION TO EMPOWER BETTER HEALTH.LAUNCH BUILDS ON 2016 COLLABORATION BETWEEN AETNA AND APPLE; ATTAIN APP IS EXPECTED TO BE AVAILABLE IN APPLE APP STORE IN SPRING 2019.  Full Article

Walmart Remains "Focused On Continuing Discussions With CVS Caremark"
Tuesday, 15 Jan 2019 

Jan 15 (Reuters) - Walmart Inc ::WALMART REMAINS "FOCUSED ON CONTINUING DISCUSSIONS WITH CVS CAREMARK AND TRYING TO FIND A SOLUTION THAT BENEFITS ALL PARTIES" - SPOKESPERSON.  Full Article

PRESS DIGEST -Wall Street Journal - July 18

July 18 The following are the top stories in the Wall Street Journal. Reuters has not verified these stories and does not vouch for their accuracy.